Collects plasma from Chinese donors and turns it into medicines that hospitals use to treat bleeding disorders, immune conditions, and severe blood loss.
What stands out
- Earnings significantly exceed cash generation
At a glance
Collects plasma from Chinese donors and turns it into medicines that hospitals use to treat bleeding disorders, immune conditions, and severe blood loss.
What this company is and how it runs — written from structure, not news.
Shanghai RAAS collects plasma from donors across China, fractionates it into albumin, immunoglobulins, and clotting factors, and sells the finished vials to Chinese hospitals. The company's output is determined entirely at the front end: China's regulator, the NMPA, licenses each collection station individually and limits donors to a specific local catchment area, so the total plasma Shanghai RAAS can gather in a year is a direct function of how many licensed stations it holds and how long it has operated them. A competitor with money can build a fractionation plant in months, but the donor trust and site-specific compliance history that fill that plant accumulate over years at each individual location and cannot be bought or moved. If the NMPA tightens its licensing rules or the donor population in any approved catchment area shrinks, those years of local presence offer no shortcut to the fresh approvals or rebuilt donor communities that the new rules would require.
How does this company make money?
The company earns money by selling individual units of albumin, immunoglobulins, and clotting factors to Chinese hospitals and medical distributors. The price it can charge for each unit is set through provincial healthcare procurement tenders and national reimbursement catalogs, which cap what hospitals are permitted to pay. Revenue therefore tracks how many licensed stations it operates, how much plasma those stations collect, and where the government sets the price ceiling at each procurement cycle.
What makes this company hard to replace?
Chinese hospitals that procure plasma products must test and trace specific product lots to meet NMPA requirements, and qualifying a new supplier's products through that process takes several months. Beyond that, each plasma-derived medicine carries its own NMPA product registration, which requires years of clinical data that a new or alternative supplier would have to generate from scratch. Established cold chain distribution arrangements between the company and Chinese medical distributors add another layer of friction that takes time to replicate.
What limits this company?
The hard ceiling on output is the number of NMPA-licensed collection stations the company holds. Each new station requires its own separate NMPA approval, tied to a specific location, and can only pull donors from the surrounding approved area. Getting that approval takes years. The company can build new fractionation equipment in months, but it cannot fill that equipment faster than the regulator approves new collection sites.
What does this company depend on?
The company cannot operate without NMPA licenses for each individual plasma collection station, Chinese plasma donors who meet NMPA eligibility criteria and keep returning on the 14-day cycle, cold ethanol chemicals and chromatography columns used to fractionate plasma, cold chain storage and transport networks to move temperature-sensitive products, and NMPA manufacturing approvals for each specific plasma-derived medicine it sells.
Who depends on this company?
Chinese hospitals treating hemophilia patients rely on its clotting factors — without domestic supply they would have to source expensive imported alternatives. Patients with immune system disorders who depend on immunoglobulin therapy would similarly need to turn to foreign-made products. Burn units and surgical centers that use albumin to stabilize patients losing blood volume would lose access to a domestically produced supply.
How does this company scale?
The conversion of plasma into finished medicines scales smoothly: as more plasma comes in, the same fixed chemical ratios reliably produce proportionally more albumin, immunoglobulins, and clotting factors. What does not scale easily is the front end — adding new collection stations requires individual NMPA site approvals that take years, and the eligible donor population within any approved catchment area is finite, so growth is always paced by the regulator's approval timeline, not by the company's capacity to process what it collects.
What external forces can significantly affect this company?
Changes to Chinese healthcare reimbursement policy can lower the maximum prices hospitals are allowed to pay for plasma products, squeezing revenue directly. At the same time, China's aging population is pushing demand for immunoglobulins and clotting factors upward, stretching supply. U.S.-China trade tensions add a background risk: if domestic supply fell short and imported plasma products became harder to source as a backup, patients could face gaps that neither the company nor the government could quickly fill.
Where is this company structurally vulnerable?
If the NMPA changed its rules to require existing collection stations to go through fresh re-approval — rather than honoring their accumulated track record — the years of local compliance history that make those stations valuable would count for little. The same damage could come from demographic shifts, tightened donor eligibility rules, or anything that disrupted the donor communities inside specific approved catchment areas, because a shrunken or scattered donor base cannot be rebuilt quickly, and no other asset the company holds would fill that gap.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations describe the present configuration: the fast moving average sits below the slow moving average, the company has been profitable for three years, and cash-flow margin is elevated.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
What the company actually pays, and whether its own cash supports it.
The reported statements, read against the company's own industry.
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and book value has increased every year for four years. The set describes a depressed-price profile alongside fundamental stability and equity accumulation.
Three observations co-occur: price is several standard deviations below its one-year mean, the company has reported positive net income every year for three years, and the equity ratio is in the elevated industry-benchmarked range. The configuration describes a depressed-price, profitable, equity-funded profile.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph